|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, differential expression analyses revealed that many genes, including AKT1 and CDK2, play important roles in melanoma.
|
30385854 |
2019 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Optimized from the purine template of seliciclib, CCT068127 exhibits greater potency and selectivity against purified CDK2 and CDK9 and superior antiproliferative activity against human colon cancer and melanoma cell lines.
|
29063678 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
|
29507054 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To identify miR-514a regulated targets we conducted a miR-514a-mRNA 'pull-down' experiment, which revealed hundreds of genes, including: CTNNB1, CDK2, MC1R, and NF1, previously associated with melanoma.
|
25980496 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, our results show how CDK2 blockade may offer a promising therapy for genetically defined melanomas, where NUAK2 is amplified and PTEN is deleted.
|
25832654 |
2015 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Such subsets of familial pancreatic cancer involve germline cationic trypsinogen or PRSS1 mutations (hereditary pancreatitis), BRCA2 mutations (usually in association with hereditary breast-ovarian cancer syndrome), CDKN2 mutations (familial atypical mole and multiple melanoma), or DNA repair gene mutations (e.g., ATM and PALB2, apart from those in BRCA2).
|
24395243 |
2014 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
It causes growth arrest in melanocytes, associated with the inhibition of Cyclin E/Cdk2 and β-catenin phosphorylation at the transcriptional activity site Ser(552) and is silenced through DNA methylation in 27/35 (77%) melanoma tissues/early cultures.
|
21649464 |
2011 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
However, three SNPs in TYR, SILV/CDK2 and ADAMTS20 genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value<0.05 when considering the whole DNA collection (1214 MM cases and 1296 controls).
|
21559390 |
2011 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Statistical significance of the observed correlations indicates that CDK-2 may be a suitable prognostic marker for melanoma and perhaps also a target for chemotherapeutic drugs.
|
17013093 |
2006 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Through DNA microarray analysis, we found that the antimelanoma effect of IFN-gamma in DM6 was associated with the down-regulation of multiple genes involved in G-protein signaling and phospholipase C activation (including Rap2B and calpain 3) as well as the down-regulation of genes involved in melanocyte/melanoma survival (MITF and SLUG), apoptosis inhibition (Bcl2A1 and galectin-3), and cell cycling (CDK2).
|
16204058 |
2005 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have therefore studied the prevalence of germline 9p deletions encompassing the CDKN2 locus in melanoma pedigrees, using multiplex ligation-dependent probe amplification.
|
16032697 |
2005 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Collectively, these data indicate that CDK2 activity in melanoma is largely maintained at the transcriptional level by MITF, and unlike other malignancies, it may be a suitable drug target in melanoma.
|
15607961 |
2004 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these data indicate that CDK2 activity in melanoma is largely maintained at the transcriptional level by MITF, and unlike other malignancies, it may be a suitable drug target in melanoma.
|
15607961 |
2004 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also examined the expression of the CDK2 gene in melanoma cell lines, to assess its possible co-regulation with the gene for the melanocyte-lineage antigen pmel17, which maps less than 1 kb away in head to head orientation with CDK2 and may be transcribed off the same bidirectional promoter.
|
11479422 |
2001 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our recent studies have demonstrated that the two tumor suppressor genes, p53 and p16/CDKN2, do not play a major role in the acquisition of the metastatic phenotype in human melanoma.
|
9810513 |
1998 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The occurrence of p16/CDKN2 germline mutations in 12 Icelandic melanoma kindreds (kindreds with two or more cases of melanoma or melanoma, pancreas and/or glioma cases) was examined.
|
10651484 |
1998 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have identified two novel CDKN2 mutations (88delG and Ala118Thr) which are likely to be associated with the development of melanoma, because of their co-segregation with the disease and their likely functional effect on the CDKN2 protein.
|
9328469 |
1997 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These data strongly support the idea that deregulation of the CDK4/cyclin D pathway, via CDKN2 or CDK4 mutations, is of biological significance in the development of melanoma.
|
9036865 |
1997 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CDKN2 is a tumor suppressor gene that is mutated in pancreatic cancers and is associated with a poorer prognosis and the development of melanoma.
|
9046882 |
1997 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although a low frequency of CDKN2 DNA aberrations was observed, the high number of tumours that lacked CDKN2 expression but showed overexpression of CDK4 and/or CCND1, suggest that functional inactivation of pRb through this pathway may be involved in the development or progression of sporadic human melanomas.
|
8611425 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A gene, CDKN2, is an appealing candidate for melanoma susceptibility.
|
8970585 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results support the following conclusions: (i) somatic mutation of the CDKN2 gene is rare in sporadic melanomas with allelic loss at 9p21; (ii) homozygous loss is more frequent than mutation of the CDKN2 gene in sporadic melanomas; (iii) at 9p21-p23 genes other than CDKN2 may be involved in the development of sporadic melanomas.
|
8631588 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As reported previously, the mutational spectrum of CDKN2 in melanomas differs from that of internal malignancies and supports the involvement of UV in melanoma tumorigenesis.
|
8834170 |
1996 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Unexpectedly, no germline CDKN2 mutations have been found in about half of the melanoma families that appear to be linked to 9p.
|
8727306 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results support an involvement of the CDKN2 product in the development of a subgroup of sporadic melanomas and encourage the search for alterations in additional genes of the 9p21 region.
|
8562340 |
1996 |